8.2 | | Barx1 | 'carotid body' vs 'adrenal medulla' | organism part | Expression profile of mouse carotid body and adrenal medulla [RNA-Seq] |
7.9 | | Barx1 | 'synovial sarcoma' vs 'control' | disease, genotype | Mouse Model of Clear Cell Sarcoma |
-7 | | Barx1 | 'acute graft vs. host disease; T-cell depleted bone marrow + T cells transplant' vs 'normal; T-cell depleted bone marrow transplant' | disease, stimulus | RNA-Seq of lymph node fibroblastic reticular cells isolated from bone marrow transplant recipient mice with or without acute Graft-versus-host disease on day 7 or untransplanted control mice |
-4.5 | | Barx1 | 'cortical epithelial cell; Lin- Dapi-EpCAM+ CD31-UEA1-Ly51+ td-tomato+t vs 'medullary epithelial cell; Lin- Dapi-EpCAM+ CD31-UEA1+Ly51- td-tomato-' | cell type, phenotype | Thymic T-cell progenitor development is supported by membrane bound Kit ligand provided by a combined vascular endothelial and epithelial niche. |
3.8 | | Barx1 | 'osteosarcoma' vs 'control' | disease, genotype | Mouse Model of Clear Cell Sarcoma |
3.3 | | Barx1 | 'Ezh1, Ezh2 Camk Cre' vs 'wild type' in '6 month' | age, genotype | Transcription profiling by array of striatal tissue of wild type and Ezh1/Ezh2 double knockout mice at 6 weeks, 3 months, and 6 months |
3.1 | | Barx1 | 'induced extraembryonic endoderm stem cell; grown in XEN cell medium' vs 'mouse embryonic fibroblast; control' | cell type, growth condition | OSKM induce extraembryonic endoderm stem (iXEN) cells in parallel to iPS cells |
2.9 | | Barx1 | 'clear cell sarcoma; TATCre' vs 'control' | disease, genotype | Mouse Model of Clear Cell Sarcoma |
2.8 | | Barx1 | 'extraembryonic endoderm stem cell; grown in XEN cell medium' vs 'mouse embryonic fibroblast; control' | cell type, growth condition | OSKM induce extraembryonic endoderm stem (iXEN) cells in parallel to iPS cells |
2.6 | | Barx1 | 'Er1F/-' vs 'wild type genotype' | genotype | RNA-Seq profiling of ERCC1-XPF DNA repair defect (Er1F/-) versus wild type (Er1F/+) macrophages |
2.3 | | Barx1 | 'induced extraembryonic endoderm stem cell; grown in ES cell medium' vs 'mouse embryonic fibroblast; control' | cell type, growth condition | OSKM induce extraembryonic endoderm stem (iXEN) cells in parallel to iPS cells |
2.3 | | Barx1 | 'extraembryonic endoderm stem cell; grown in ES cell medium' vs 'mouse embryonic fibroblast; control' | cell type, growth condition | OSKM induce extraembryonic endoderm stem (iXEN) cells in parallel to iPS cells |
1.6 | | Barx1 | 'Sall4 homozygous knockout' vs 'wild type genotype' | genotype | RNA-Seq of Sall4 mutants in mouse embryonic stem cells |
1.6 | | Barx1 | 'induced neuronal cell' vs 'pluripotent embryonic stem cell' | phenotype | Transcription profiling by high throughput sequencing of retinoic acid-differentiated neuronal cells compared to nondifferentiated pluripotent embryonic stem cells |
1.5 | | Barx1 | 'Aire knockout' vs 'wild type' in 'mTEClo' | genotype, phenotype | Transcription profiling by high throughput sequencing of primary cTEC, mTEClo, and mTEChi harvested from wild type and Aire-deficient mice |
-1.5 | | Barx1 | 'etoposide; 2.5 micromolar' vs 'none' in 'H2afj-∆7-KO' | compound, genotype | RNA-seq of H2afj-ko and isogenic WT C57/Bl6-N mouse embryonic fibroblasts in proliferation and after etoposide-induced senescence. |
1.5 | | Barx1 | 'CD36 knockout' vs 'wild type genotype' in 'oxidized low density lipoprotein; 25 microgram per milliliter' | compound, genotype | Quantitative analysis of wild type and cd36-/- murine peritoneal macrophage transcriptomes |
1.3 | | Barx1 | 'CD36 knockout' vs 'wild type genotype' in 'none' | compound, genotype | Quantitative analysis of wild type and cd36-/- murine peritoneal macrophage transcriptomes |
1.2 | | Barx1 | 'Ezh1, Ezh2 Camk Cre' vs 'wild type' in '3 month' | age, genotype | Transcription profiling by array of striatal tissue of wild type and Ezh1/Ezh2 double knockout mice at 6 weeks, 3 months, and 6 months |
-1.2 | | Barx1 | '9V/null' vs 'wild type' in 'saline; spleen' | compound, genotype, organism part | Gaucher Disease: Transcriptome Analyses Using Microarray or mRNA Sequencing in a Mouse Model Treated with velaglucerase alfa or imiglucerase [RNA-Seq] |